IFN-α2a was the first approved cytokine for the treatment of chronic myeloid leukemia (Italian Cooperative Study Group on Chronic Myeloid Leukemia, Tura et al., 1994), since type I IFNs have broad immunomodulatory activity. This evidence concerns the gene IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive.